CinCor Pharma, Inc., (CINC): Price and Financial Metrics
GET POWR RATINGS... FREE!
CINC Stock Price Chart Interactive Chart >
CINC Price/Volume Stats
| Current price | $28.89 | 52-week high | $43.15 |
| Prev. close | $28.93 | 52-week low | $10.53 |
| Day low | $28.75 | Volume | 361,800 |
| Day high | $29.16 | Avg. volume | 801,567 |
| 50-day MA | $19.05 | Dividend yield | N/A |
| 200-day MA | $24.21 | Market Cap | 1.26B |
CinCor Pharma, Inc., (CINC) Company Bio
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardiovascular diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension and primary aldosteronism, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Latest CINC News From Around the Web
Below are the latest news stories about CINCOR PHARMA INC that investors may wish to consider to help them evaluate CINC as an investment opportunity.
CinCor Pharma Inc. (CINC): Is It Worth A Small Bite At $28.95?CinCor Pharma Inc. (NASDAQ:CINC) price on Friday, January 13, fall -0.41% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $28.95. A look at the stock’s price movement, the close in the last trading session was $29.07, moving within a range at $28.765 and $29.05. Turning to its … CinCor Pharma Inc. (CINC): Is It Worth A Small Bite At $28.95? Read More » |
Why These Two Biotech Stocks Blasted Higher This WeekTwo somewhat under-the-radar biotech companies saw their share prices soar this week after agreeing to be acquired. CinCor Pharma (NASDAQ: CINC) is being bought out by deep-pocketed pharmaceutical company AstraZeneca, while Albireo Pharma (NASDAQ: ALBO) is set to be owned by France-based peer Ipsen. Both of these deals are very lucrative, to the point where CinCor's stock rocketed 146% over the course of the week, and Albireo shot 92% skyward, according to data compiled by S&P Global Market Intelligence. |
Do investors need to be concerned about CinCor Pharma Inc. (CINC)?The share price of CinCor Pharma Inc. (NASDAQ:CINC) rose to $28.80 per share on Tuesday from $28.74. While CinCor Pharma Inc. has overperformed by 0.21%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CINC rose by 80.00%, with highs and lows ranging from $43.15 to $10.53, […] |
AstraZeneca Is Acquiring CinCor Pharma: Market Values Interesting CVR At $3.21AstraZeneca is acquiring Cincor Pharma for $26 per share and an interesting CVR. Learn more about the acquisition and my recommendation. |
Biotech Stock Roundup: REGN Down on Eylea Data, CINC Surges on AZN Offer & MoreUpdates from Regeneron (REGN) and CinCor Pharma (CINC) are the key highlights from the biotech sector during the past week. |
CINC Price Returns
| 1-mo | 145.87% |
| 3-mo | -3.92% |
| 6-mo | 23.20% |
| 1-year | 53.92% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 135.07% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...